Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response
Authors
Keywords
Regulatory T cells, Cyclophosphamide, Melanoma, Immunotherapy
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume 62, Issue 5, Pages 897-908
Publisher
Springer Nature
Online
2013-04-16
DOI
10.1007/s00262-013-1397-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Levels of peripheral CD4+FoxP3+ regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer
- (2012) X. Yao et al. BLOOD
- Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
- (2012) Eva Ellebaek et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides
- (2012) P. Filipazzi et al. CLINICAL CANCER RESEARCH
- Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?
- (2012) Joannes FM Jacobs et al. LANCET ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
- (2012) Vivian L. Weiss et al. PLoS One
- Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
- (2011) Yingzi Ge et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Unraveling Cancer Chemoimmunotherapy Mechanisms by Gene and Protein Expression Profiling of Responses to Cyclophosphamide
- (2011) F. Moschella et al. CANCER RESEARCH
- T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells
- (2011) Guoyan Cheng et al. IMMUNOLOGICAL REVIEWS
- Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study
- (2011) Renee Vermeij et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine
- (2011) Craig L. Slingluff et al. JOURNAL OF CLINICAL ONCOLOGY
- Functional Plasticity of Antigen-Specific Regulatory T Cells in Context of Tumor
- (2011) C. Addey et al. JOURNAL OF IMMUNOLOGY
- IL-2 Contributes to Maintaining a Balance between CD4+Foxp3+ Regulatory T Cells and Effector CD4+ T Cells Required for Immune Control of Blood-Stage Malaria Infection
- (2011) F. Berretta et al. JOURNAL OF IMMUNOLOGY
- Plasticity of Human Regulatory T Cells in Healthy Subjects and Patients with Type 1 Diabetes
- (2011) Stephanie A. McClymont et al. JOURNAL OF IMMUNOLOGY
- Identification of T helper type 1–like, Foxp3+ regulatory T cells in human autoimmune disease
- (2011) Margarita Dominguez-Villar et al. NATURE MEDICINE
- Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
- (2011) John Koreth et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T cell plasticity: beyond the controversies
- (2011) Shohei Hori TRENDS IN IMMUNOLOGY
- Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents
- (2010) I. J. M. de Vries et al. CLINICAL CANCER RESEARCH
- LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
- (2010) C. Camisaschi et al. JOURNAL OF IMMUNOLOGY
- Low-dose Cyclophosphamide Treatment Impairs Regulatory T Cells and Unmasks AFP-specific CD4+ T-cell Responses in Patients With Advanced HCC
- (2010) Tim F. Greten et al. JOURNAL OF IMMUNOTHERAPY
- Clinical Use of Anti-CD25 Antibody Daclizumab to Enhance Immune Responses to Tumor Antigen Vaccination by Targeting Regulatory T cells
- (2009) Andrew J. Rech et al. Annals of the New York Academy of Sciences
- Tumor Antigen-Specific FOXP3+ CD4 T Cells Identified in Human Metastatic Melanoma: Peptide Vaccination Results in Selective Expansion of Th1-like Counterparts
- (2009) C. Jandus et al. CANCER RESEARCH
- Quantitative DNA Methylation Analysis of FOXP3 as a New Method for Counting Regulatory T Cells in Peripheral Blood and Solid Tissue
- (2009) G. Wieczorek et al. CANCER RESEARCH
- Membrane protein GARP is a receptor for latent TGF-β on the surface of activated human Treg
- (2009) Julie Stockis et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Comparison of stable human Treg and Th clones by transcriptional profiling
- (2009) Julie Stockis et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines
- (2009) Jens Ruter Frontiers in Bioscience-Landmark
- Functional Delineation and Differentiation Dynamics of Human CD4+ T Cells Expressing the FoxP3 Transcription Factor
- (2009) Makoto Miyara et al. IMMUNITY
- Prolonged Survival of Dendritic Cell–Vaccinated Melanoma Patients Correlates With Tumor-Specific Delayed Type IV Hypersensitivity Response and Reduction of Tumor Growth Factor β-Expressing T Cells
- (2009) Mercedes N. López et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulatory T cells and treatment of cancer
- (2008) Tyler J Curiel CURRENT OPINION IN IMMUNOLOGY
- Tumor-specific regulatory T cells in cancer patients
- (2008) Sytse J. Piersma et al. HUMAN IMMUNOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now